MSH|^~\&|NBS^2.16.840.1.114222.4.3.4.12.3^ISO|IDAHO^2.16.840.1.114222.4.1.3651^ISO|PHINCDS^2.16.840.1.114222.4.3.2.10^ISO|PHIN^2.16.840.1.114222^ISO|20200504094020.768||ORU^R01^ORU_R01|NOT10443637ID012020-05-04T09:40:20.768|P|2.5.1|||||||||NOTF_ORU_v3.0^PHINProfileID^2.16.840.1.114222.4.10.3^ISO~Generic_MMG_V2.0^PHINMsgMapID^2.16.840.1.114222.4.10.4^ISO~Lyme_TBRD_MMG_V1.0^PHINMsgMapID^2.16.840.1.114222.4.10.4^ISOPID|1||PSN1ID^^^NBS&2.16.840.1.114222.4.3.4.12.3&ISO||~^^^^^^S||19920618000000.000|F||2106-3^White^2.16.840.1.113883.6.238|^^^16^^^^^16001|||||||||||2186-5^Not Hispanic or Latino^2.16.840.1.113883.6.238|||||||20171022000000.000OBR|1|""|CAS10475000ID01^NBS^2.16.840.1.114222.4.3.4.12.3^ISO|68991-9^Epidemiologic Information^LN|||20190627111757.667|||||||||||||||20190627111757.667|||F||||||11090^Anaplasma phagocytophilum^2.16.840.1.114222.4.5.277OBX|1|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|1|25064002^Headache^2.16.840.1.113883.6.96||||||FOBX|2|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|1|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|3|CWE|255633001^Treatment Drug Indicator^2.16.840.1.113883.6.96^255633001^Were antibiotics prescribed?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|4|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|2|271737000^Anemia^2.16.840.1.113883.6.96||||||FOBX|5|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|2|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|6|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|3|271807003^Rash^2.16.840.1.113883.6.96||||||FOBX|7|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|3|N^No^2.16.840.1.113883.12.136||||||FOBX|8|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|4|302215000^Thrombocytopenia^2.16.840.1.113883.6.96||||||FOBX|9|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|4|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|10|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|5|386661006^Fever^2.16.840.1.113883.6.96||||||FOBX|11|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|5|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|12|CWE|418912005^Transfusion Associated^2.16.840.1.113883.6.96^418912005^Was the patients infection transfusion associated?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|13|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|6|419188005^Leukopenia^2.16.840.1.113883.6.96||||||FOBX|14|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|6|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|15|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|7|68962001^Myalgia^2.16.840.1.113883.6.96||||||FOBX|16|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|7|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|17|CWE|82312-0^Blood Transfusion^2.16.840.1.113883.6.1^82312_0^Has the subject received a blood transfusion in the 12 months prior to this illness?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|18|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|8|87319000^Eschar^2.16.840.1.113883.6.96||||||FOBX|19|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|8|N^No^2.16.840.1.113883.12.136||||||FOBX|20|CWE|95898004^Tick Bite^2.16.840.1.113883.6.96^95898004^In the eight weeks before symptom onset or diagnosis, did the patient notice any tick bites?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|21|CWE|105470007^Blood Donor^2.16.840.1.113883.6.96^ARB005^Did the patient donate blood in the 30 days prior to symptom onset?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|22|CWE|161663000^Organ Transplant^2.16.840.1.113883.6.96^ARB008^In the year before symptom onset of diagnosis, did the subject receive an organ transplant(s)?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|23|CWE|78746-5^Country of Birth^2.16.840.1.113883.6.1^DEM126^Country of Birth^L||USA^UNITED STATES^1.0.3166.1||||||FOBX|24|ST|77969-4^Jurisdiction Code^2.16.840.1.113883.6.1^INV107^Jurisdiction^L||Health District 4||||||FOBX|25|DT|77995-9^Date Reported^2.16.840.1.113883.6.1^INV111^Date of Report^L||20170916||||||FOBX|26|CWE|48766-0^Reporting Source Type Code^2.16.840.1.113883.6.1^INV112^Reporting Source Type^L||PHC252^Other State and Local Agencies^2.16.840.1.114222.4.5.274||||||FOBX|27|ST|52831-5^Reporting Source Zip Code^2.16.840.1.113883.6.1^INV118^Zip^L||83703||||||FOBX|28|TS|77972-8^Earliest Date Reported to County^2.16.840.1.113883.6.1^INV120^Earliest Date Reported to County^L||20170916000000.000||||||FOBX|29|TS|77973-6^Earliest Date Reported to State^2.16.840.1.113883.6.1^INV121^Earliest Date Reported to State^L||20170916000000.000||||||FOBX|30|CWE|INV1266^Occupation Related to Exposure^2.16.840.1.114222.4.5.232^INV1266^Is exposure related to current occupation?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|31|CWE|77974-4^Hospitalized^2.16.840.1.113883.6.1^INV128^Was the patient hospitalized for this illness?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|32|TS|8656-1^Admission Date^2.16.840.1.113883.6.1^INV132^Admission Date^L||20170916000000.000||||||FOBX|33|TS|8649-6^Discharge Date^2.16.840.1.113883.6.1^INV133^Discharge Date^L||20170922000000.000||||||FOBX|34|SN|78033-8^Duration of Hospital Stay in Days^2.16.840.1.113883.6.1^INV134^Total Duration of Stay in the Hospital (in days)^L||^6||||||FOBX|35|TS|77975-1^Diagnosis Date^2.16.840.1.113883.6.1^INV136^Diagnosis Date^L||20170916000000.000||||||FOBX|36|TS|11368-8^Date of Illness Onset^2.16.840.1.113883.6.1^INV137^Illness Onset Date^L||20170915000000.000||||||FOBX|37|TS|77976-9^Illness End Date^2.16.840.1.113883.6.1^INV138^Illness End Date^L||20170922000000.000||||||FOBX|38|SN|77977-7^Illness Duration^2.16.840.1.113883.6.1^INV139^Illness Duration^L||^7|d^Day^2.16.840.1.113883.6.8|||||FOBX|39|CWE|77978-5^Subject Died^2.16.840.1.113883.6.1^INV145^Did the patient die from this illness?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|40|DT|77979-3^Case Investigation Start Date^2.16.840.1.113883.6.1^INV147^Investigation Start Date^L||20170916||||||FOBX|41|CWE|77980-1^Case Outbreak Indicator^2.16.840.1.113883.6.1^INV150^Is this case part of an outbreak?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|42|CWE|77989-2^Transmission Mode^2.16.840.1.113883.6.1^INV157^Transmission Mode^L||418427004^Vector-borne transmission^2.16.840.1.113883.6.96||||||FOBX|43|CWE|77990-0^Case Class Status Code^2.16.840.1.113883.6.1^INV163^Case Status^L||410605003^Confirmed present^2.16.840.1.113883.6.96||||||FOBX|44|SN|77991-8^MMWR Week^2.16.840.1.113883.6.1^INV165^MMWR Week^L||^38||||||FOBX|45|DT|77992-6^MMWR Year^2.16.840.1.113883.6.1^INV166^MMWR Year^L||2017||||||FOBX|46|ST|77993-4^State Case Identifier^2.16.840.1.113883.6.1^INV173^State Case ID^L||340||||||FOBX|47|CWE|77996-7^Pregnancy status^2.16.840.1.113883.6.1^INV178^Is the patient pregnant?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|48|ST|74549-7^Person Reporting to CDC - Name^2.16.840.1.113883.6.1^INV190^Person Reporting to CDC - Name^L||noname||||||FOBX|49|ST|74548-9^Person Reporting to CDC - Phone Number^2.16.840.1.113883.6.1^INV191^Person Reporting to CDC - Phone Number^L||208-000-0000||||||FOBX|50|ST|77997-5^Legacy Case Identifier^2.16.840.1.113883.6.1^INV200^Legacy Case ID^L||3402000000000||||||FOBX|51|SN|77998-3^Age at case investigation^2.16.840.1.113883.6.1^INV2001^Reported Age^L||^32|a^year [time]^2.16.840.1.113883.6.8|||||FOBX|52|CWE|77983-5^Country of Usual Residence^2.16.840.1.113883.6.1^INV501^Country of Usual Residence^L||USA^UNITED STATES^1.0.3166.1||||||FOBX|53|CWE|INV1265^Experienced Complication^2.16.840.1.114222.4.5.232^INV920^Did the patient experience any severe complications?^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|54|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|9|OTH^Other Symptom Indicator^2.16.840.1.113883.5.1008^^^^^^Nausea, vomiting||||||FOBX|55|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|9|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|56|CWE|77966-0^Reporting State^2.16.840.1.113883.6.1^NOT109^Reporting State^L||16^Idaho^2.16.840.1.113883.6.92||||||FOBX|57|CWE|77968-6^National Reporting Jurisdiction^2.16.840.1.113883.6.1^NOT116^National Reporting Jurisdiction^L||16^Idaho^2.16.840.1.113883.6.92||||||FOBX|58|CWE|77965-2^Immediate National Notifiable Condition^2.16.840.1.113883.6.1^NOT120^Immediate National Notifiable Condition^L||N^No^2.16.840.1.113883.12.136||||||FOBX|59|CWE|INV929^Clinical Manifestation^2.16.840.1.114222.4.5.232^INV929^Clinical Manifestation^L|10|PHC2108^Hepatic transaminase elevation^2.16.840.1.114222.4.5.274||||||FOBX|60|CWE|INV930^Clinical Manifestation Indicator^2.16.840.1.114222.4.5.232^INV930^Clinical Manifestation Indicator^L|10|Y^Yes^2.16.840.1.113883.12.136||||||FOBX|61|CWE|420008001^Travel^2.16.840.1.113883.6.96^TRAVEL02^Did patient travel out of their country, state, or country of residence prior to illness onset?^L||N^No^2.16.840.1.113883.12.136||||||FOBX|62|CWE|370388006^Patient Immunocompromised^2.16.840.1.113883.6.96^VAR126^Patient immunocompromised at time of diagnosis^L||Y^Yes^2.16.840.1.113883.12.136||||||FOBX|63|ST|INV933^Immunocompromised Associated Condition or Treatment^2.16.840.1.114222.4.5.232^VAR127^Immunocompromised associated condition or treatment^L||Cancer, chemotherapy||||||FOBX|64|DT|14687-8^Blood Transfusion Date^2.16.840.1.113883.6.1^14687_8^Blood Transfusion Date^L|1|20170815||||||FOBX|65|CWE|29303-5^Medication Administered^2.16.840.1.113883.6.1^29303_5^Antibiotic Prescribed^L|1|3640^Doxycycline^2.16.840.1.113883.6.88||||||FOBX|66|CWE|66746-9^Specimen Type^2.16.840.1.113883.6.1^667469^Specimen Type^L|1|119364003^Serum^2.16.840.1.113883.6.96||||||FOBX|67|SN|67453-1^Treatment Duration^2.16.840.1.113883.6.1^67453_1^Treatment Duration (in days)^L|1|^10|d^day^UCUM|||||FOBX|68|ST|68994-3^Performing Laboratory Name^2.16.840.1.113883.6.1^68994_3^Performing Laboratory Name^L|1|IDBOL||||||FOBX|69|ST|85078-4^Current Industry^2.16.840.1.113883.6.1^85078_4^Current Industry^L|1|Education||||||FOBX|70|CE|85657-5^Current Industry Standardized^2.16.840.1.113883.6.1^85657_5^Current Industry Standardized^L|1|7860^Elementary and secondary schools [7860]^2.16.840.1.114222.4.5.315||||||FOBX|71|ST|85658-3^Current Occupation^2.16.840.1.113883.6.1^85658_3^Current Occupation^L|1|Teacher||||||FOBX|72|CE|85659-1^Current Occupation Standardized^2.16.840.1.113883.6.1^85659_1^Current Occupation Standardized^L|1|2310^Elementary and middle school teachers [2310]^2.16.840.1.114222.4.5.314||||||FOBX|73|CWE|INV1269^Laboratory State^2.16.840.1.114222.4.5.232^INV1269^Laboratory State^L|1|16^Idaho^2.16.840.1.113883.6.92||||||FOBX|74|DT|86948-7^Date the treatment was prescribed^2.16.840.1.114222.4.5.232^INV1300^Date Antibiotic Prescribed^L|1|20170916||||||FOBX|75|CWE|INV290^Test Type^2.16.840.1.114222.4.5.232^INV290^Test Type^L|1|23877-4^IFA IgG Anaplasma Phagocytophilum^2.16.840.1.113883.6.1||||||FOBX|76|CWE|INV291^Test Result^2.16.840.1.114222.4.5.232^INV291^Test Result^L|1|260385009^Negative^2.16.840.1.113883.6.96||||||FOBX|77|CWE|77984-3^Country of Exposure^2.16.840.1.113883.6.1^INV502^Country of Exposure^L|1|USA^UNITED STATES^1.0.3166.1||||||FOBX|78|CWE|77985-0^State or Province of Exposure^2.16.840.1.113883.6.1^INV503^State or Province of Exposure^L|1|16^Idaho^2.16.840.1.113883.6.92||||||FOBX|79|ST|77986-8^City of Exposure^2.16.840.1.113883.6.1^INV504^City of Exposure^L|1|unknown||||||FOBX|80|ST|77987-6^County of Exposure^2.16.840.1.113883.6.1^INV505^County of Exposure^L|1|Ada, ID||||||FOBX|81|ST|LAB202^Performing Laboratory Specimen ID^2.16.840.1.114222.4.5.232^LAB125^Performing Laboratory Specimen ID^L|1|11111||||||FOBX|82|TS|68963-8^Specimen Collection Date/Time^2.16.840.1.113883.6.1^LAB163^Specimen Collection Date^L|1|20170916000000.000||||||FOBX|83|CWE|LAB278^Organism Name^2.16.840.1.114222.4.5.232^LAB278^Organism Name^L|1|420364006^Anaplasma Phagocytophilum^2.16.840.1.113883.6.96||||||FOBX|84|ST|LAB628^Test Result Quantitative^2.16.840.1.114222.4.5.232^LAB628^Test Result Quantitative^L|1|<1:64||||||FOBX|85|CWE|66746-9^Specimen Type^2.16.840.1.113883.6.1^667469^Specimen Type^L|2|119376003^Tissue^2.16.840.1.113883.6.96||||||FOBX|86|ST|68994-3^Performing Laboratory Name^2.16.840.1.113883.6.1^68994_3^Performing Laboratory Name^L|2|CDC RZB Reference Laboratory||||||FOBX|87|CWE|INV1269^Laboratory State^2.16.840.1.114222.4.5.232^INV1269^Laboratory State^L|2|13^Georgia^2.16.840.1.113883.6.92||||||FOBX|88|CWE|INV290^Test Type^2.16.840.1.114222.4.5.232^INV290^Test Type^L|2|29560-0^PCR Anaplasma Phagocytophilum^2.16.840.1.113883.6.1||||||FOBX|89|CWE|INV291^Test Result^2.16.840.1.114222.4.5.232^INV291^Test Result^L|2|10828004^Positive^2.16.840.1.113883.6.96||||||FOBX|90|ST|LAB202^Performing Laboratory Specimen ID^2.16.840.1.114222.4.5.232^LAB125^Performing Laboratory Specimen ID^L|2|33333||||||FOBX|91|TS|68963-8^Specimen Collection Date/Time^2.16.840.1.113883.6.1^LAB163^Specimen Collection Date^L|2|20170918000000.000||||||FOBX|92|CWE|LAB278^Organism Name^2.16.840.1.114222.4.5.232^LAB278^Organism Name^L|2|420364006^Anaplasma Phagocytophilum^2.16.840.1.113883.6.96||||||FOBX|93|CWE|66746-9^Specimen Type^2.16.840.1.113883.6.1^667469^Specimen Type^L|3|119376003^Tissue^2.16.840.1.113883.6.96||||||FOBX|94|ST|68994-3^Performing Laboratory Name^2.16.840.1.113883.6.1^68994_3^Performing Laboratory Name^L|3|CDC RZB Reference Laboratory||||||FOBX|95|CWE|INV1269^Laboratory State^2.16.840.1.114222.4.5.232^INV1269^Laboratory State^L|3|13^Georgia^2.16.840.1.113883.6.92||||||FOBX|96|CWE|INV290^Test Type^2.16.840.1.114222.4.5.232^INV290^Test Type^L|3|LAB608^Other Test Type^2.16.840.1.114222.4.5.232^^^^^^ImmunoHistoChemistry||||||FOBX|97|CWE|INV291^Test Result^2.16.840.1.114222.4.5.232^INV291^Test Result^L|3|10828004^Positive^2.16.840.1.113883.6.96||||||FOBX|98|ST|LAB202^Performing Laboratory Specimen ID^2.16.840.1.114222.4.5.232^LAB125^Performing Laboratory Specimen ID^L|3|33333||||||FOBX|99|TS|68963-8^Specimen Collection Date/Time^2.16.840.1.113883.6.1^LAB163^Specimen Collection Date^L|3|20170918000000.000||||||FOBX|100|CWE|LAB278^Organism Name^2.16.840.1.114222.4.5.232^LAB278^Organism Name^L|3|420364006^Anaplasma Phagocytophilum^2.16.840.1.113883.6.96||||||FOBX|101|DT|77970-2^Date First Reported PHD^2.16.840.1.113883.6.1^INV177^Date First Reported PHD^L||20170916||||||FOBR|2|""|903422222^^2.16.840.1.114222.4.3.4.12.3^ISO|T-15750^Rickettsia spotted fever group antibody^2.16.840.1.114222.4.3.4.12.3|||20170914000000.000|||||||||||||||20170914000000.000|||FOBX|1|TX|T-58735^Rickettsia rickettsii - Result^2.16.840.1.114222.4.3.4.12.3|1|Anaplasma||||||F|||20170914000000.000SPM|1|||119364003^Serum^2.16.840.1.113883.6.96||||87100004^Unknown Body Region^2.16.840.1.113883.6.96||||||Serum|||20170914000000.000
